BUSINESS

Nihon Medi-Physics’ Project to Develop Labeled Antibody Therapeutics Selected for AMED’s CiCLE Grant Program

April 4, 2018

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Nihon Medi-Physics announced on April 3 that its development project for labeled antibody therapeutics (alpha ray) and companion diagnostics has been selected by the Japan Agency for Medical Research and Development’s (AMED) Cyclic Innovation for Clinical Empowerment (CiCLE) grant program.…

To read the full story

With CiCLE Program Entering 2nd Year, AMED Should Release More Information on Grant Program
February 28, 2018
AMED Begins Taking Applications for Funding for Drug Discovery Environments
March 17, 2017

BUSINESS

Eylea Bio-AG Snags 60% Share in Just 3 Months, Outpacing Biosimilar
May 29, 2026
FRONTEO, Scohia Team Up on AI-Driven Indication Discovery
May 29, 2026
AGC Biologics Launches Bispecific Antibody CDMO Project in Japan
May 28, 2026
Bayer Regulatory Chief Hails Japan’s Review System, Flexibility on PI Waivers
May 28, 2026
Asahi Kasei Licenses ADC Technology from Noguchi Institute
May 28, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…